Compare Novartis AG (NVS) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Open Text Corporation — how do they compare? Novartis AG trades at $140.04 (market cap $262.28B), while Open Text Corporation trades at $22.88 (market cap $5.49B). The key difference: Novartis AG is far larger — about 47.8× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.95%). Which is the better fit depends on your goals.
| NVS | OTEX | |
|---|---|---|
Market Cap | $262.28B | $5.49B |
Sector | Health | Technology |
52-Week High | $168.62 | $39.69 |
52-Week Low | $121.80 | $20.01 |
Enterprise Value | $303.60B | $10.51B |
Dividend Yield | 3.45% | 4.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
Open Text Corporation (OTEX) trades at $23.36, down 2.46% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 8.77 and consistent earnings beats in recent quarters. Recent news highlights a 4.3% decline on September 1, 2026, while the company continues cloud revenue growth and strategic AI investments.
OTEX presents a value opportunity with attractive valuation metrics and solid profitability, but faces near-term technical pressure. The consensus price target of $29.33 suggests 25% upside potential, though investors should monitor debt levels and competitive pressures in the enterprise software sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
